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Stargardt disease (STGD) is a common autosomal recessive maculopathy of early and young-adult onset and is
caused by alterations in the gene encoding the photoreceptor-specific ATP-binding cassette (ABC) transporter
(ABCA4). We have studied 144 patients with STGD and 220 unaffected individuals ascertained from the German
population, to complete a comprehensive, population-specific survey of the sequence variation in the ABCA4 gene.
In addition, we have assessed the proposed role for ABCA4 in age-related macular degeneration (AMD), a common
cause of late-onset blindness, by studying 200 affected individuals with late-stage disease. Using a screening strategy
based primarily on denaturing gradient gel electrophoresis, we have identified in the three study groups a total of
127 unique alterations, of which 90 have not been previously reported, and have classified 72 as probable pathogenic
mutations. Of the 288 STGD chromosomes studied, mutations were identified in 166, resulting in a detection rate
of ∼58%. Eight different alleles account for 61% of the identified disease alleles, and at least one of these, the
L541P-A1038V complex allele, appears to be a founder mutation in the German population. When the group with
AMD and the control group were analyzed with the same methodology, 18 patients with AMD and 12 controls
were found to harbor possible disease-associated alterations. This represents no significant difference between the
two groups; however, for detection of modest effects of rare alleles in complex diseases, the analysis of larger
cohorts of patients may be required.
Introduction
Stargardt disease (STGD [MIM 248200]) is an auto-
somal recessive macular dystrophy causing progressive
impairment of central vision, with onset typically in
childhood or young adulthood. Affected individuals dis-
play atrophic macular lesions, as well as characteristic
yellowish flecks in the macular and perimacular region
(Stargardt 1909). Recently, the photoreceptor cell–
specific ATP-binding cassette transporter (ABCA4, for-
merly ABCR [MIM 601691]) gene was identified and
found to be mutated in patients with STGD (Allikmets
et al. 1997b). ABCA4 codes for a 2,273-amino-acid pro-
tein, previously characterized as the photoreceptor rim
protein (Papermaster et al. 1978) and localizing to the
rims of the rod and cone outer-segment disks (Sun and
Nathans 1997; Molday et al. 2000). A member of the
ABC-transporter superfamily of proteins, which are in-
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volved in the energy-dependent transport of substrates
across membranes, ABCA4 is thought to flip N-retinyl-
idene-phosphatidylethanolamine from the lumenal to
the cytosolic face of the photoreceptor disks (Sun et al.
1999; Weng et al. 1999).
Several series of mutation analyses have confirmed
that ABCA4 is the gene underlying STGD and have
initiated a characterization of the mutational spectrum
(Nasonkin et al. 1998; Rozet et al. 1998; Fishman et
al. 1999; Lewis et al. 1999; Maugeri et al. 1999; Pa-
paioannou et al. 2000; Simonelli et al. 2000). Overall,
in patients with STGD, standard techniques based pri-
marily on SSCP screening or heteroduplex analysis, fol-
lowed by direct DNA sequencing of aberrant fragments,
identify mutations in ∼60% of ABCA4 alleles (e.g., see
Lewis et al. 1999; Maugeri et al. 1999). The majority
of mutations are missense, followed by nonsense mu-
tations, small insertions/deletions, and mutations af-
fecting RNA splicing. Certain mutant alleles—for ex-
ample, G863A, A1038V, and G1961E—appear to be
more common and may have altered frequencies in dif-
ferent populations, as a result of founder effect (Maug-
eri et al. 1999; Simonelli et al. 2000).
ABCA4 has also been evaluated as a possible cause
for other diseases with similar pathology in the macula.
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Gene mutations have been observed in families mani-
festing cone-rod dystrophy (CRD) and/or atypical ret-
initis pigmentosa (RP) (Cremers et al. 1998; Martinez-
Mir et al. 1998). Of great interest has been an analysis
that noted an increased frequency of heterozygous
ABCA4 alterations in individuals with age-related mac-
ular degeneration (AMD) (Allikmets et al. 1997a), a
common multifactorial condition in the elderly popu-
lation (Bressler et al. 1988). This investigation has been
the subject of dispute (Dryja et al. 1998; Klaver et al.
1998), and a subsequent study, comparable in scope,
refuted an association (Stone et al. 1998). Taking an
alternate approach, Souied et al. (2000) analyzed the
segregation of ABCA4 variants in 52 multiplex cases of
AMD and concluded that they may be a predisposing
factor in ∼4% of cases. Recently, an international con-
sortium screening for two common variants in the
ABCA4 gene in 11,200 patients with AMD and asmany
controls confirmed a significantly increased frequency
of both alterations in the group with AMD (Allikmets
and The International ABCR Screening Consortium
2000). Given the substantial burden of this disease, with
7.1% of individuals age 175 years affected with late-
stage AMD (Klein et al. 1992) and an estimated mutant
ABCA4-heterozygote frequency of 2%–3% in the gen-
eral population (Dean et al. 1998), the clarification of
the role of ABCA4 in AMD becomes a critical issue.
We have undertaken a comprehensive analysis of the
ABCA4 gene in 144 unrelated patients with STGD, 200
unrelated patients with AMD, and 220 control individ-
uals, all ascertained from the German population. Un-
der an identical screening protocol for each group, we
have carefully catalogued the sequence variations both
in disease alleles and in normal alleles. This forms a
population-specific base of data that will increase the
diagnostic and prognostic value of molecular-genetic
analysis in STGD and will provide additional infor-
mation on the issue of ABCA4 involvement in the path-
ogenesis of AMD.
Subjects and Methods
Subjects
A total of 144 individuals with STGD were included
in the study. All patients are unrelated, with the excep-
tion of two (STGD139 and STGD139b), a mother-
daughter pair demonstrating pseudodominant inheri-
tance because of consanguinity in the family. Each
patient has been evaluated by one of the authors
(H.P.N.S, E.A.-S., B.L., or B.J.), at the Eye Care Centre,
Vancouver (by D. Walker), or at the Eye Clinic Benjamin
Franklin, Berlin (by U. Kellner). Examination included
ascertainment of personal and family history, measure-
ment of visual acuity, fundus examination, electroretin-
ography, and, in some cases, fluorescein angiography.
The diagnosis of STGD was based on the demonstration
of bilateral impairment of central vision and the ap-
pearance of perimacular and/or peripheral yellow-white
flecks, with or without atrophy of the central retinal-
pigment epithelium and a normal or only mildly ab-
normal flash electroretinogram when recorded in early
stages of the disease. In addition, for all patients inwhom
both disease alleles were identified, blood samples from
the parents and from other affected family members
were obtained, whenever possible.
The AMD study group consists of 200 individuals
from two different geographic regions of Germany (Hei-
delberg and Mu¨nster). Diagnosis of AMD was based on
an international classification and grading system (Bird
et al. 1995). The group represents a broad clinical spec-
trum, with 100 individuals having geographic atrophy
(“dry” AMD) and 100 individuals having exudative
(“wet”) AMD, and has been described elsewhere (Kra¨-
mer et al. 2000). The average age of the group with
AMD is 75.6 years (range 55–93 years). We selected as
a control group 153 unaffected individuals matched for
age (mean 76.2 years, range 34–102 years) and geo-
graphic region. All were seen in the same clinics as the
patients with AMD, but for nonretinal disease. After
examination of the fundus, only individuals with fewer
than five hard drusen and no other signs of AMD were
included. A further 67 unselected, population-based con-
trols (mean age 51.2 years, range 21–87 years) were
included, bringing the total number of individuals in the
control group to 220. Each of the three study groups
reflects the current ethnic mixture present in the German
population, in which the representation by individuals
of other nationalities is ∼10% (Statistisches Bundesamt
Deutschland).
Mutation Analysis
All 50 exons of the ABCA4 gene were screened using
a combination of denaturing gradient gel electrophoresis
(DGGE) (Fodde and Losekoot 1994), denaturing high-
performance liquid chromatography (dHPLC) (Liu et al.
1998), and SSCP analysis (Orita et al. 1989). For each
sample, genomic DNA was isolated from peripheral
blood leukocytes, according to standard protocols. The
individual coding exons and flanking intron sequences
were PCR amplified with the oligonucleotide primers
and conditions listed in table 1. Primer sequences pub-
lished elsewhere (Allikmets et al. 1997b) are identifiable
by name. For each exon analyzed by DGGE, GC clamps
(5′-CGC CCG CCG CGC CCC GCG CCC GTC CCG
CCG CCC CCG CCC G-3′) were applied to either the
forward or the reverse primer. Reactions were carried
out for 33 cycles in a 1.0- or 1.5-mMMgCl2-containing
buffer with or without 4% formamide.
Table 1
Oligonucleotide Primers and Conditions
ANALYSIS
AND
EXON
FORWARD PRIMER REVERSE PRIMER
ANNEALING
TEMPERATURE
(C)
MgCl2
(mM)bNamea
Sequence
(5′–3′) Namea
Sequence
(5′–3′)
DGGE:
1 ABCR1-For AATCTGGTCTTCGTGTGGTC ABCR1-GC GTTTATTTGCTCCACACCTC 58 1.0
2 ABCR2-GC AATCTCTTAGCACCACTGAAC ABCR2-Rev AGGCCCAGACCAAAGTCTC 58 1.0
3 ABCR3-For CCTGCTTGGTCTCCATGAC ABCR3-GC ACGTGAAGGGGTGTGCAAC 57 1.0
4 ABCR4-GC2 CCTTATTAATGAGGCTTTGTC ABCR4-Rev2 ATAGGTGAGGGAAATGATGC 57 1.5
5 ABCR5-GC CCATTTCCCCTTCAACACCC ABCR5-Rev GTGCTTCCCTCCCCTCCAG 58 1.0
6 ABCR6-For CTACCACAGGGCAGTTTCTA ABCR6-GC CAGGAATCACCTTGCAATTG 58 1.0
7 ABCR7-GC GATCAGACTG TGCCTATGTG ABCR7-Rev ATAAGTGGGGTAAATGGTGG 57 1.0
9 ABCR9-GC AGGTTACAAGCAATGGGGAG ABCR9-Rev TCTGGGAGGTCCAGGGTAC 58 1.0
12 ABCR12-For AGTTGAGTCTTTGCAGTTGG ABCR12-GC CTGACTTTGGAGAAATGCAG 58 1.5
13 ABCR13-GC TCGGGAGGTGTGAGTGAGC ABCR13-Rev TTAGCGTGTCATGGAGGAGG 58 1.0
14 ABCR14-GC2 ATTCTGCCTCTACCAGGTAC ABCR14-rev AATCCAGGCACATGAACAGG 57 1.5
15 12-For AGGCTGGTGGGAGAGAGC ABCR15-GC GGACTGCTACGGACCATTC 56 1.5
16 13-For CTGTTGCATTGGATAAAAGGC ABCR16-GC GATGAATGGAGAGGGCTGG 56 1.5
17 Exon J-For CTGCGGTAAGGTAGGATAGGG ABCR17-GC CACACCGTTTACATAGAGGGC 58 1.5
18 Exon K-For CTCTCCCCTCCTTTCCTG ABCR18-GC2 GCCTTTTCCTCGCCTCTG 56 1.0
19 15-For TGGGGCCATGTAATTAGGC ABCR19-GC TGGGAAAGAGTAGACAGCCG 57 1.5
19 ABCR19-For2 AAGATTTTTGAGCCCTGTGG ABCR19-GC TGGGAAAGAGTAGACAGCCG 57 1.5
20 ABCR20-GC GCCCTCCTAAGGCATGTTG 2F3-Rev TATCTCTGCCTGTGCCCAG 57 1.0
21 2R5N-For GTAAGATCAGCTGCTGGAAG ABCR21-GC GAAGCTCTCCTGCTCCAAGC 58 1.0
22 2F5R-For2 AGGTACCCCCACAATGCC ABCR22-GC AGCCCAGCCCAGGAGACT 56 1.0
23 ABCR23-GC TTTTTGCAACTATATAGCCAGG 2F6-Rev AGCCTGTGTGAGTAGCCATG 58 1.5
24 2F7R-For GCATCAGGGAGAGGCTGTC ABCR24-GC CCAGACGGAACCCAAGTATG 59 1.0
25 ABCR25-GC GGTAACCTCACAGTCTTCC 23F1-Rev GGGAACGATGGCTTTTTGC 56 1.5
26 ABCR26-GC2 TCCCATTATGAAGCAATACC ABCR26-Rev CCTTAGACTTTCGAGATGG 48 1.5
28 ABCR28-GC ACGTGTGACATCTCCATGCC ABCR28-Rev CCCTTCTAAGCAGCATGTGA 58 1.0
29 ABCR29-GC AGGCTCTGAGTTGCATGATG ABCR29-Rev CTGCCATCTTGAACCCACC 59 1.0
31 ABCR31-For TATAAGTCCTCAAGTTCCAAG ABCR31-GC AATATCTTCTACAGGGAGCC 56 1.5
32 ABCR32-For TAACGGCACTGCTGTACTTG ABCR32-GC TCATGGCTGTGAGGTGTGC 58 1.0
33 33G1-For TTCATGTTTCCCTACAAAACCC ABCR33-GC AAAATCCTACTCAAATCTCCAG 58 1.5
34 ExA-For GCTTAACTACCATGAATGAG ABCR34-GC TCAGCAGGAGGAGGGATG 56 1.0
35 ABCR35-GC TAACTAGCTGTTAATGCAGCG ExB-Rev AAGAGTGGAGAAGGTGACAA 58 1.5
36 ABCR36-GC GTATCTTCTCCTCCTTCTGC ABCR36-Rev CACACAAGCTCCACCTTGG 58 1.5
37 ABCR37-GC CAGGTCTGAGAGGTTAAGTG ABCR37-Rev CCACCAGGCTTCTCTTCAG 58 1.0
39 ABCR39-For2 GGTTTGCCCCGTTTCCAAC ABCR39-GC TCCCAGCTTTGGACCCAG 56 1.0
40 ABCR40-GC AGGTCTGTGGGGTGAGCTG ABCR40-Rev TCTGGATGCCCTGAGCTGC 58 1.0
41 ABCR41-For GAAAGGACAGTGCCAAGGAC ABCR41-GC TCTAACCAGCACCTCCAAAC 58 1.5
42 ABCR42-GC CCGTCTCAGTTCTCAGTCC ABCR42-Rev AGAGCTGATGTTCGGAAGCC 57 1.0
43 4RX-For CTTACCCTGGGGCCTGAC ABCR43-GC TCAGAGCCACCCTACTATAG 56 1.5
45 ABCR45-GC CTTGTCTTCTCCAAATGGCA ABCR45-Rev TTTAAGCCCTTGGTGCGGC 51 1.0
46 E1R-For GAAGCAGTAATCAGAAGGGC ABCR46-GC CCTCACATTCTTCCATGCTG 57 1.0
47 ABCR47-For CACATCCCACAGGCAAGAG ABCR47-GC ATCCACAGAAGGCAACAAGG 57 1.0
48 ABCR48-GC AGGCCCAACCACTAACAGAG E3F-Rev ACACTGGGTGTTCTGGACC 57 1.0
50 ABCR50-GC AAACCAAGATGACGCGAGTC ABCR50-Rev GGAACGAGCGGTGTGAAAG 57 1.0
dHPLC:
8 ABCR8F2 GAGCATTGGCCTCACAGCAG ABCR8R2 CCCCAGGTTTGGTTTCACC 54 1.0
27 ABCR27F2 GAGATCCAGACCTTATAGGC 23F3R GTTATAACCCATGCCTGAAG 54 1.5
30 ABCR30F2 ACTTTGAGGCTGATTATGGAA ABCR30R CCCCGTTGTTTGGAGGTC 54 1.5
38 ABCR38F2 GGAATGGAATGTGGAACTCC ABCR38R2 ACACATACTCTACTATCCTAC 54 1.5
44 62r4F GAAGCTTCTCCAGCCCTAGC 62r3R TGCACTCTCATGAAACAGGC 54 1.0
49 ABCR49F GTGTAGGGTGCTGTTTTCC ABCR49R CAAGCTGTGGACTGCATAAG 54 1.5
SSCP:
10 ABCR10F4 ATCTTTGTCTGGTTTTAGGC ABCR10R4 CCCCCCTTACTCTGATCAT 50 1.5
11 ABCR11F2 GAATTTCTAAGCAGAGCAGTG ABCR11R AGCTCTGGCCCCACTCATG 54 1.5
a GC p GC clamp at the 5′ end of the respective primer.
b PCR reaction with () or without () 4% formamide.
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Exons 1–7, 9, 12–26, 28, 29, 31–37, 39–43, 45–48,
and 50 were analyzed by DGGE. Between 30 and 50 ml
of each GC-clamped PCR product was loaded onto a
6% polyacrylamide gel with a 20%–70% or 0%–70%
gradient of urea and formamide. The gels were run for
6 h at 150 V in TAE buffer (40 mM Tris base, 20 mM
glacial acetic acid, and 1 mM EDTA, pH 8.0) at 60C,
before being stained with ethidium bromide and pho-
tographed under UV transillumination.
Several exons resolved poorly with DGGE and were
analyzed by other methods. dHPLC with the WAVE
DNA Fragment Analysis System (Transgenomic) was
used to analyze exons 8, 27, 30, 38, 44, and 49. PCR
products (4–8 ml) were injected and eluted from the col-
umn with a linear acetonitrile gradient at a constant flow
of 0.9 ml/min. The optimal temperature for resolution
of homoduplex and heteroduplex DNA was determined
by injecting the PCR product for each exon at increasing
temperatures until the sample retention time decreased.
Exons 10 and 11 required the use of SSCP analysis. Exon
10 was analyzed as a single fragment, and exon 11 was
analyzed as two fragments, cleaved with restriction en-
zyme AluI prior to gel loading. In brief, 3 ml of a 1:5
mixture of [32P]-dCTP radiolabeled PCR product and
loading buffer (95% formamide, 0.1% xylene cyanol,
and 0.1% bromophenol blue) were denatured for 3 min
and were run on a 6% nondenaturing polyacrylamide
gel in 0.5# TBE (45 mM Tris-HCl, 45 mM boric acid,
and 1 mM Na2EDTA, pH 8.3) buffer with 5% glycerol
at 4C and 25 W for 3–6 h. After drying of the gel,
detection was achieved by autoradiography.
For each of the techniques applied, all aberrant frag-
ments were directly DNA sequenced with the Big-Dye
Terminator Cycle Sequencing Ready Reaction Kit (PE
Biosystems) and an ABI 310 automated sequencer. Sim-
ilarly, for two additional patients with STGD (STGD40/
163 and STGD47/164), the 50 exonic PCR products of
ABCA4 were sequenced using the respective forward
and reverse oligonucleotide primers.
Analysis of Splicing Mutations
The functional consequences of five identified
splice-site alterations—IVS205GrA, IVS2310TrG,
IVS285GrA, IVS3810TrC, and IVS405 GrA—
were studied with the Exon Trapping System pSPL3b
(Gibco Life Technology). In each case, the region en-
compassing the affected splice site and the adjacent
exon(s) was PCR amplified from the patient’s genomic
DNA by the following oligonucleotide primer pairs: for
IVS20, ABCR20EcoRI-linkF (5′-CCG GAA TTC GCC
CTC CTA AGG CAT GTT G-3′) and ABCR20BamHI-
linkR (5′-CGC GGA TCC TAT CTC TGC CTG TGC
CCA G-3′); for IVS23, ABCR23EcoRI-linkF (5′-CCG
GAA TTC TTT TTG CAA CTA TAT AGC CAG G-3′)
and ABCR24BamHI-linkR (5′-CGC GGA TCC CCA
GAC GGA ACC CAA GTA TG-3′); for IVS28,
ABCR28EcoRI-linkF (5′-CCG GAA TTC ACG TGT
GAC ATC TCC ATG CC-3′) and ABCR28BamHI-linkR
(5′-CGC GGA TCC CCC TTC TAA GCA GCA TGT
GA-3′); for IVS 38, ABCR39EcoRI-linkF (5′-CCG GAA
TTC GCC CCA CCT GCT GAA GAG-3′) and
ABCR39BamHI-linkR (5′-CGC GGA TCC TCC CAG
CTT TGG ACC CAG G-3′); and for IVS40,
ABCR39EcoRI-linkF and ABCR40BamHI-linkR (5′-
CGC GGA TCC TCT GGA TGC CCT GAG CTG C-
3′). EcoRI and BamHI recognition sequences were cou-
pled to the forward and reverse primers, respectively, to
ensure directional insertion into the pSPL3b vector.
Wild-type and mutant clones were selected for trans-
formation into COS7 cells. After 48 h, mRNA was iso-
lated from the COS7 cells and was analyzed by reverse
transcription (RT)–PCR using either vector primer SA2
(5′-ATC TCA GTG CTA TTT GTG AGC-3′) and nested
primer SA4 (5′-CAC CTG AGG AGT GAA TTG GTC
G-3′) or SD6 (5′-TCT GAG TCA CCT GGA CAA CC-
3′) and nested primer SD2 (5′-GTG AAC TGC ACT
GTG ACA AGC-3′), as well as exon-specific primers. All
RT-PCR products were electrophoresed on a 1%agarose
gel, and their sequences were determined after excision
of the respective fragments.
Results
Using a combination of DGGE, dHPLC, and SSCP
screening, we studied 288 ABCA4 alleles from patients
with STGD, 400 alleles from patients with AMD, and
440 alleles from the control group, and we identified
2,365 sequence changes (on average, 5.77 alterations per
patient with STGD, 3.52 per patient with AMD, and
3.77 per control individual).
Classification of Sequence Alterations
Definition of a “disease-associated” mutation is a dif-
ficult task, particularly if functional assays to determine
phenotypic effects of specific variations are not readily
available (Cotton and Scriver 1998). For the purposes
of this study, we have used the following defining cri-
teria. ABCA4 sequence alterations whose predicted con-
sequence is premature truncation of the protein—that
is, nonsense mutations, small insertions, or deletions
causing a frameshift—and alterations affecting splicing
were classified as disease-associated mutations. Also
considered pathological were missense mutations caus-
ing nonconservative amino acid changes—for example,
A60T and A60E (table 2)—with the exception of those
that were found at similar frequencies in the three study
groups—for example, R152Q, N1868I, and V1921M
(tables 3 and 4). Nucleotide alterations occurring in sim-
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Table 2
ABCA4 Mutations Found in Patients with STGD and AMD and in Controls
EXON AND
NUCLEOTIDE
CHANGE EFFECT
NO. OF ALLELES
REFERENCE(S)
STGD
(288)
AMD
(400)
Control
(440)
3:
178GrA A60T 1 0 0 This study
179CrT A60E 1 0 0 This study
194GrA G65E 1 0 0 Fishman et al. (1999)
203CrT P68L 1 0 0 This study
214GrA G72R 1 0 0 This study
296insA Frameshift 2 0 0 This study
5:
454CrT R152X 1 0 0 This study
6:
634CrT R212C 1 0 0 Lewis et al. (1999)
688TrA C230S 1 0 0 This study
730delCT Frameshift 1 0 0 This study
740ArG N247S 1 0 0 This study
768GrT Splice 2 0 0 Maugeri et al. (1999)
8:
983ArT E328V 1a 0 0 This study
1086TrA Y362X 1 0 0 This study
10:
1317GrA W438X 1 0 0 This study
11:
1411GrA E471K 1 0 0 Lewis et al. (1999)
12:
1622TrC L541P 21a 1a 0 Rozet et al. (1998), Fishman et al. (1999), Lewis et al. (1999),
Maugeri et al. (1999)
1715GrA R572Q 1a 0 0 Lewis et al. (1999)
13:
1819GrA G607R 1 0 0 This study
1903CrA Q635K 2a 0 0 This study
1903CrT Q635X 1 0 0 This study
IVS131GrA Splice 2 0 0 This study
14:
1957CrT R653C 1 0 0 This study
1988GrA W663X 1 0 0 This study
2041CrT R681X 4 0 0 Maugeri et al. (1999)
15:
2291GrA C764Y 1 0 0 This study
2292delT Frameshift 1a 0 0 This study
2295TrG S765R 1a 0 0 This study
16:
2564GrA W855X 1 0 0 Nasonkin et al. (1998)
17:
2588GrC Spliceb 17a 6 5 Allikmets et al. (1997a), Cremers et al. (1998), Lewis et al.
(1999), Maugeri et al. (1999), Papaioannou et al. (2000)
18:
2701ArG T901A 0 2 0 This study
2741ArG H914A 0 0 1 This study
19:
2876CrT T959I 1 0 0 This study
20:
IVS205GrA Splice 1 0 0 This study
21:
3106GrA E1036K 1a 0 0 Nasonkin et al. (1998)
3113CrT A1038V 26a 4a 1 Allikmets et al. (1997a), Cremers et al. (1998), Rozet et al.
(1998), Fishman et al. (1999), Lewis et al. (1999), Maugeri et
al. (1999)
T3187TrC S1063P 1 0 0 This study
(Continued)
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Table 2 Continued
EXON AND
NUCLEOTIDE
CHANGE EFFECT
NO. OF ALLELES
REFERENCE(S)
STGD
(288)
AMD
(400)
Control
(440)
22:
3292CrT R1097C 1 0 0 This study
3322CrT R1108C 4 0 0 Rozet et al. (1998), Fishman et al. (1999), Lewis et al. (1999)
24:
3528insTGCA Frameshift 1 0 0 This study
25:
3808GrT E1270X 1 0 0 This study
27:
3898CrT R1300X 1 0 0 This study
28:
IVS285GrA Splice 1 0 0 This study
4139CrT P1380L 1 0 0 Lewis et al. (1999)
4195GrA E1399K 2 0 0 This study
4234CrT Q1412X 4 0 0 Maugeri et al. (1999)
29:
4289TrC L1430P 2 0 0 This study
4318TrG F1440V 1 0 0 This study
4328GrA R1443H 1 0 0 This study
30:
4457CrT P1486L 1 0 0 Lewis et al. (1999)
4463GrA C1488Y 1 0 0 This study
31:
4610CrT T1537M 1 0 0 This study
35:
IVS352TrA Splice 1 0 0 This study
36:
5065TrC S1689P 1 0 0 This study
5114GrT R1705L 1 0 0 This study
IVS361GrA Splice 1 0 0 This study
37:
5198TrC M1733T 0 0 1 This study
5242GrA G1748R 1 0 0 This study
5248CrT Q1750X 1 0 0 This study
5288TrC L1763P 1 0 0 This study
38:
IVS381GrA Splice 1 0 0 This study
40:
5653GrA E1885K 1 0 0 This study
5693GrA R1898H 5 2 1 Allikmets et al. (1997b), Lewis et al. (1999)
IVS405GrA Splice 8a 0 0 Cremers et al. (1998), Lewis et al. (1999), Maugeri et al. (1999)
42:
5882GrA G1961E 34 4 2 Allikmets et al. (1997b), Fishman et al. (1999), Lewis et al.
(1999), Maugeri et al. (1999)
43:
5917delG Frameshift 3 0 0 This study
5923GrC G1975R 1 0 0 This study
5929GrA G1977S 1 0 0 Rozet et al. (1998), Lewis et al. (1999)
45:
6229CrG R2077G 1 0 0 This study
6229CrT R2077W 1 0 0 Allikmets et al. (1997a), Fishman et al. (1999), Lewis et al.
(1999)
48:
6609CrA Y2203X 2 0 0 This study
6647GrT A2216V 0 0 1 This study
a Mutation pairs occurring on a single haplotype.
b Effect is missense mutation (G863A) and in-frame deletion (delG863), according to Maugeri et al. (1999).
Table 3
Rare Sequence Variants in the ABCA4 Gene
EXON AND
NUCLEOTIDE
CHANGE EFFECT
NO. OF ALLELES
REFERENCE(S)
STGD
(288)
AMD
(400)
Control
(440)
5:
455GrA R152Q 3 1 3 This study
8:
IVS838ArT Unknown 0 1 0 This study
12:
1654GrA V552I 0 0 2 This study
IVS116CrG Unknown 0 4 2 This study
13:
1932CrT D644D 2 0 0 This study
17:
IVS1612CrG Unknown 0 0 8 This study
18:
IVS1756CrG Unknown 3 0 0 This study
IVS1736CrT Unknown 0 2 1 This study
22:
3261ArC E1087D 1 0 0 This study
3264CrT P1088P 0 0 1 This study
IVS2120CrT Unknown 1 0 0 This study
23:
IVS2310TrG Unknown 1 0 0 This study
IVS2317GrC Unknown 1 0 0 This study
24:
IVS2328TrC Unknown 2 4 1 This study
25:
3759GrA T1253T 1 0 0 This study
28:
4140GrA P1380P 2 0 0 This study
IVS2843GrA Unknown 4 3 1 This study
29:
IVS2913GrA Unknown 0 1 0 This study
IVS2932ArG Unknown 1 0 0 This study
31:
4578GrA T1526T 0 1 0 This study
32:
IVS3245TrC Unknown 1 0 0 This study
33:
IVS3257TrG Unknown 0 0 1 This study
4685TrC I1562T 0 0 6 Allikmets et al. (1997b)
36:
IVS3620GrA Unknown 1 0 0 This study
39:
5487GrT L1829L 0 0 1 This study
IVS3810TrC Unknown 9 0 0 Maugeri et al. (1999)
41:
5761GrA V1921M 1 1 1 This study
43:
5908CrT L1970F 1 0 1 Allikmets et al. (1997b), Rozet et al. (1998), Lewis et al. (1999)
IVS437ArC Unknown 1 0 0 This study
44:
6027CrT I2023I 1 0 0 Allikmets et al. (1997a), Nasonkin et al. (1998)
45:
6176GrC G2059A 0 0 1 This study
46:
IVS4627GrA Unknown 0 0 1 This study
47:
IVS4646TrA Unknown 1 0 0 This study
48:
IVS4821CrT Unknown 18a 2a 0 Allikmets et al. (1997b), Nasonkin et al. (1998), Papaioannou et al. (2000)
6529GrA D2177N 2 3 4 Allikmets et al. (1997b)
6721CrG L2241V 1 0 0 This study
a Occurs together with G1961E in 17/18 and 2/2 instances.
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Table 4
Polymorphisms in the ABCA4 Gene
EXON AND
NUCLEOTIDE
CHANGE EFFECT
NO. OF ALLELES
REFERENCE(S)
STGD
(n p 288)
AMD
(n p 400)
Control
(n p 440)
6:
635GrA R212H 8 8 32 This study
7:
IVS632TrC Unknown 53 115 130 This study
10:
1267ArG H423R 52 79 101 This study
1268CrT H423H 11 17 17 This study
14:
IVS1450TrCa Unknown 22 18 9 This study
19:
2828GrAa R943Q 23 14 10 Allikmets et al. (1997a, 1997b), Maugeri et al. (1999),
Papaioannou et al. (2000)
28:
4203CrA P1401P 29 13 20 Maugeri et al. (1999)
33:
IVS3238CrT Unknown 1 4 12 This study
34:
IVS3316delGT Unknown 24 8 12 This study
40:
5603ArT N1868I 37 40 46 Maugeri et al. (1999)
5682GrC L1894L 73 52 91 Maugeri et al. (1999), Papaioannou et al. (2000)
41:
5814ArG L1938L 50 68 70 This study
42:
IVS4111GrA Unknown 46 56 55 Maugeri et al. (1999)
5844ArG P1948P 40 40 39 Maugeri et al. (1999), Papaioannou et al. (2000)
5843CArTG P1948L 5 14 13 Maugeri et al. (1999)
44:
IVS4316GrA Unknown 46 48 55 Papaioannou et al. (2000)
45:
IVS457GrA Unknown 10 15 11 Papaioannou et al. (2000)
6249CrT I2083I 13 17 27 Allikmets et al. (1997a), Maugeri et al. (1999)
46:
6285TrC D2095D 38 36 33 Maugeri et al. (1999)
a 2828GrA and IVS1450TrC occur on the same haplotype together with 2588GrC.
ilar frequencies and found in 11% of the control alleles
were regarded to be polymorphic. All remaining changes
were categorized as rare sequence variants with unclas-
sifiable pathogenicity.
ABCA4 Mutations in STGD, AMD, and Controls
In 288 STGD chromosomes, we identified 191 dis-
ease-associated mutations (table 2). Missense mutations
make up the majority (76.4%), followed by nonsense
(9.9%), splice (9.4%), and frameshift (4.2%)mutations.
Fifty mutations occurred as part of 25 complex alleles,
resulting in a total of 166 disease chromosomes and an
overall detection rate of 57.6%. Both alleles were de-
tected in 59 patients (40.9%), a single disease allele was
found in 48 patients (33.3%), and no disease allele was
identifiable in 37 patients (25.7%).
In the group with AMD, 400 chromosomes were stud-
ied and 19 mutations were identified, with L541P and
A1038V occurring on a single haplotype in one patient
(AMD43). In the control group, 440 chromosomes were
analyzed, and 12 mutations were detected.Missense var-
iants were the only mutation type found in the group
with AMD and in the control group (table 2).
ABCA4 Rare Sequence Variants and Polymorphisms in
Patients with Either STGD or AMD and in Controls
Thirty-six different alterations detected in either the
group with STGD or the group with AMD or the control
group were considered to be rare sequence variants of
unknown pathogenicity (table 3). More than half of
these alterations were detected in the intervening se-
quences, and, although they are less likely to be path-
ogenic, a possible effect on RNA splicing cannot be ruled
out. One such alteration, IVS4821CrT, appears to be
present at a significantly higher frequency in the popu-
lation with STGD; however, the frequency is increased
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Figure 1 Evaluation of consequences of intervening sequence alterations: results of RT-PCR analyses (a) and schematic representations
(b–f), indicating abnormal splicing at mutant splice site IVS205GrA (b and d) and normal splicing at mutant splice sites IVS2310TrG and
IVS3810TrC (c and e). Clone IVS405GrA reveals both normal and abnormal splicing products, suggesting partial activity at the mutant
site (a and f). The relative positions of the forward (⇀)and reverse (↼) RT-PCR primers, mutant sites (*), and the cryptic splice site in the
pSPL3b vector sequence () are indicated. For sizing of RT-PCR products, the 100-bp ladder is given, and spans range 100–500 bp.
because of linkage disequilibrium with the mutation
G1961E (data not shown). Nineteen different alterations
were present in 11% of the control alleles and were
classified as polymorphisms (table 4); these include
five nonconservative amino acid substitutions (R212H,
H423R, R943Q, N1868I, and P1948L).
Evaluation of Splice-Site Alterations IVS205GrA,
IVS2310TrG, IVS285GrA, IVS3810TrC, and
IVS405GrA
Five different intronic alterations found in patients
with STGD but not in either patients with AMD or in
controls were evaluated for their effects on RNA splic-
ing. Three alterations (IVS205GrA, IVS285GrA,
and IVS405GrA) affect the highly conserved G at
the 5 position of splice donor sites. In this series,
IVS205GrA and IVS285GrA were each found in
one patient with STGD, and IVS405GrA was found
in eight patients with STGD. Another alteration, at the
10 position of the intervening sequence-23 splice do-
nor site (IVS2310TrG), was found in a single patient
with STGD. The fifth alteration affects the10 position
of a splice-acceptor site (IVS3810TrC) and was ob-
served in nine patients with STGD. We used an exon-
trapping system to introduce DNA fragments encom-
passing each affected splice site and adjacent exon(s) into
COS7 cells. For both wild-type and mutant sequences,
the resulting splicing of the RNA products was then
studied by nested RT-PCR analysis and direct sequencing
(fig. 1).
The RT-PCR product amplified from COS7 cell
RNA containing the IVS205GrA alteration results
in a fragment of 412 bp and was confirmed, by DNA
sequencing, to include exon 20 and sequence from
intron 20, indicating that the mutation abolishes cor-
rect splicing at the normal donor site and, instead,
leads to the activation of a cryptic splice site within
the pSPL3b vector sequence (fig. 1a and b). In con-
trast, an RT-PCR product of 204 bp was obtained
from an appropriately spliced RNA derived from the
corresponding wild-type clone (fig. 1a and b). Like-
wise, for the intron 28 alteration, a spliced product
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Table 5
Patients with STGD Who Have Two Identified Disease Alleles
AGE AT ONSET
AND PATIENT
MUTATION
SEGREGATION IN
FAMILYaAllele 1 Allele 2
5–9 years:
STGD17 Q1412X R2077W Yes
STGD88 G65E G1961E NA
STGD93 G1961E G1961E Yes
STGD99 L541P-A1038V G1961E Yes
STGD100 L541P-A1038V IVS405GrA Yes
STGD108 Y362X IVS405GrA Yes
STGD109 L541P-A1038V W855X Yes
STGD139b 5917delG 5917delG Yes
STGD167 C1488Y IVS405GrA Yes
10–14 years:
STGD21 R681X R1898H NA
STGD37 L541P-A1038V L541P-A1038V Yes
STGD47/164 IVS131GrA 2588GrC Yes
STGD50 2588GrC A1038V NA
STGD70 2588GrC IVS405GrA NA
STGD82 L541P-A1038V S1063P Yes
STGD87 2588GrC Q1750X Yes
STGD98 R212C T959I Yes
STGD102 R572Q-2588GrC IVS352TrA Yes
STGD107 C764Y 3528ins4 Yes
STGD120 L1430P L1430P NA
STGD121 R1300X IVS405GrA Yes
STGD156 R1108C G1961E NA
STGD159 R1108C Q1412X Yes
STGD171 L541P-A1038V G1961E NA
15–19 years:
STGD34 G768T G1961E Yes
STGD39 L541P-A1038V R1443H NA
STGD40/163 2588GrC E1885K Yes
STGD45 E1399K G1977S Yes
STGD59 R1898H G1975R NA
STGD67 P68L S1689P Yes
STGD75 Q635K IVS405GrA Yes
STGD111 2292delT-S765R G1961E Yes
STGD114 Y2203X G1961E Yes
STGD138 IVS131GA 2588GrC Yes
20–24 years:
STGD41 R681X G1961E Yes
STGD63 A60T R1898H NA
STGD86 296insA G1961E Yes
STGD91 L541P-A1038V A1038V NA
STGD113 L541P-A1038V 2588GrC Yes
STGD118b IVS205GrA G1961E Yes
STGD119 L541P-A1038V G1961E Yes
STGD122 L541P-A1038V G1961E Yes
STGD135 W663X G1961E NA
STGD147 IVS361GrA G1961E Yes
STGD168 L541P-A1038V G1961E NA
25–29 years:
STGD62 G607R G1961E NA
STGD71 296insA A1038V Yes
STGD78 2588GrC Q1412X Yes
STGD103 2588GrC IVS205GrA Yes
STGD116 L541P-A1038V G1961E Yes
STGD139bb G1961E 5917delG Yes
30 years:
STGD38 E471K G1961E Yes
STGD68 E1399K G1961E Yes
STGD69 L541P-A1038V 2588GrC NA
STGD95 F1440V G1748R Yes
STGD134 C230S G1961E NA
STGD144 2588GrC R1705L NA
STGD148 R1097C Y2203X NA
STGD170 L541P-A1038V 2588GrC NA
a NA p not applicable.
b 139b and 139 are a mother-daughter pair.
(200 bp) was produced from the wild-type clone,
whereas a larger abnormally spliced product (369 bp)
was obtained from the IVS285GrA mutant clone
(fig. 1a and d). The demonstration, in this system, of
abnormal splicing in both mutant clones, compared
with normal splicing in the wild-type clones, allowed
us to classify both alterations, IVS205GrA and
IVS285GrA, as disease-associated mutations. The
IVS405GrA mutant clone yielded two different
fragments, a larger abnormally spliced product (350
bp) and a smaller, correctly spliced product (200 bp)
identical to that obtained from the wild-type clone
(fig. 1a and f). This provides experimental evidence
for the suggestion by Cremers et al. (1998) that IVS
405GrA does not represent a true null allele but,
because of correct splicing at the IVS405GrA site
in a percentage of transcripts, results in residual ac-
tivity of the ABCA4 transporter protein.
RT-PCR amplification of COS7 cell RNAs yielded
391-bp products (exons 23 and 24) from both the wild-
type and IVS2310TrG clones (fig. 1a and c) and
yielded 105-bp products (exon 39) from both the wild-
type and IVS38-10TrC clones (fig. 1a and e). DNA
sequencing confirmed that all fragments represent cor-
rectly spliced exons. In agreement with these findings,
additional RT-PCR analysis with RNA derived from
an Epstein-Barr virus–transformed lymphoblastoid cell
line from a patient (STGD169) heterozygous for the
IVS3810TrC alteration did not detect any aberrant
splicing (data not shown). These results led us to classify
the IVS2310TrG and IVS3810TrC alterations as
rare sequence variants.
Patients with STGD Who Have Two Identified Disease
Chromosomes
Fifty-nine patients with STGD were found to be ho-
mozygotes or compound heterozygotes for ABCA4 dis-
ease alleles (table 5). Correct segregation of disease al-
leles was demonstrated in all 39 cases in which family
samples were available for study (table 5). In 11 of these
families, segregation was confirmed in multiple affected
members, whereas in the remaining cases the study was
limited to the demonstration of correct parental trans-
mission of disease alleles.
The majority of patients are compound heterozygotes
for twomissense mutations (31/59 patients ) or one trun-
cating and one missense mutation (25/59 patients). Two
patients, STGD108 and STGD121, are heterozygous for
both an alteration in the donor splice site of intron 40
(IVS405GrA) and a nonsense mutation (STGD108,
Y362X and STGD121, R1300X). STGD108 had disease
onset at age 9 years, and at last examination (age 13
years), significant visual impairment (OD/OS0.08/0.08),
moderate fundus changes, and perimacular and periph-
eral flecks. STGD121 had disease onset at age 10 years
and, at age 27 years, visual acuity of 0.07/0.1 (OD/OS)
and moderate fundus changes with perimacular and pe-
ripheral flecks and pigment clumping nasal to the optic
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nerve. Both eyes exhibited extensive central retinal pig-
ment epithelium atrophy. Both patients have normal
electrodiagnostic values. One patient (STGD139) is a
homozygote for a 1-bp deletion, 5917delG. She had on-
set of disease at age 5 years and, on examination at age
10 years, visual acuity of 0.8/0.8 (OD/OS), mild fundus
changes, and abnormal electroradiography values sug-
gestive of both rod and cone involvement (rod response
[OU] and 30-Hz flicker [OD] amplitudes !50% of the
5th percentile; 30-Hz flicker latency [OU] 1150% of the
95th percentile).
Discussion
We have provided the results of a comprehensive mu-
tation analysis of the 50 exons of the ABCA4 gene in
144 patients with STGD, 200 individuals diagnosedwith
AMD, and 220 controls, all ascertained from the
German population. This study has addressed a number
of important issues. First, since, in the studies conducted
to date, the detection rate of ABCA4 alterations has been
below expectations, we aimed to develop an improved
and efficient screening protocol withmaximal sensitivity.
Second, by describing a large number of sequence al-
terations in the ABCA4 gene in affected individuals and
controls, we provided a survey of alterations that facil-
itates the categorizing of disease-associated mutations
versus benign polymorphisms or rare sequence variants
with unclear pathogenicity and that adds to the growing
amount of data correlating genotype with phenotype.
Third, we established a mutation profile for the German
population that will aid in ABCA4 gene testing and risk
assessment for STGD. Finally, we compare the sequence
alterations found in each of the three sample groups, to
further evaluate the much debated role of ABCA4 in the
pathogenesis of AMD.
A total of 127 unique alterations in the ABCA4 gene
were identified, of which 90 have not been described
elsewhere; 110 distinct changes were present in patients
with STGD, 36 in patients with AMD, and 42 in control
individuals. We have classified 72 of these alterations
as probable pathogenic mutations, because of their pre-
dicted deleterious effects on the protein. Nineteen al-
terations were defined as common polymorphisms,
whereas 36 distinct alterations were classified as rare
sequence variants, since their contribution to disease is
uncertain and remains to be clarified. As well as changes
not affecting the specificity of amino acid residues and
conservative amino acid substitutions, included in the
latter category are some rare nonconservative changes
found in similar frequencies in the three study
groups—for example, R152Q, V1921M, and L1970F.
Under our definitions, the conservative amino acid al-
teration D2177N, which has been described elsewhere
as associated with AMD (Allikmets et al. 1997a; Allik-
mets and the International ABCR ScreeningConsortium
2000), was also classified as a rare sequence variant. In
the present study, however, it was found at similar fre-
quencies in patients with either STGD or AMD and in
controls (2/288, 3/400, and 4/440 alleles, respectively),
which neither supports nor refutes a role for this mu-
tation in disease. A notable finding is the high frequen-
cies in the control group of two independent alterations,
IVS16-12CrG (1.8%) and I1562T (1.4%), in contrast
to their complete absence in the group with STGD as
well as in the group with AMD. Although IVS16-
12CrG has not been reported elsewhere, I1562T has
been found two times in patients with AMD but not in
those with STGD or in 220 controls (Allikmets et al.
1997a). Larger study numbers may be required in order
to determine the significance of these findings.
Of the 72 distinct pathogenic mutations, 68 were
found in the group with STGD and account for 166
disease chromosomes. Although the majority of mu-
tations are rare, found in only one or two families,
three disease alleles (2588GrC, L541P-A1038V, and
G1961E) are present at high frequencies in the German
population. The most frequent is G1961E, which rep-
resents 34 (20.5%) of 166 identified alleles, a frequency
that is significantly higher than the 4%–9% reported in
other studies (Allikmets 1997a; Lewis et al. 1999;
Maugeri et al. 1999; Simonelli et al. 2000). Notable is
the presence of a patient with STGD (STGD93) who is
homozygous for this mutation, a combination of alleles
that has been speculated not to result in a STGD phe-
notype (Simonelli et al. 2000). The second-most-fre-
quent allele is a complex allele, with A1038V occurring
on the same haplotype as L541P (21/166 [12.7%]). Al-
though the A1038V mutation is commonly reported in
the literature, the L541P-A1038V complex allele has
been reported only five times (Rozet et al. 1998; Fish-
man et al. 1999; Lewis et al. 1999; Maugeri et al. 1999).
Given the relatively high frequency in the population
that we studied, it is likely to represent a German foun-
der allele. The third-most-frequent allele is 2588GrC,
representing 10.2% (17/166) of identified disease chro-
mosomes. These three alterations, in combination with
five others (R681X, A1038V as noncomplex allele,
R1108C, Q1412X, R1898H, and IVS405GrA), ac-
count for 61.4% of the detectable disease chromosomes
in the German patients with STGD.
The 2588GrC transversion is a relatively common
mutation, with an allele frequency of 1/17 in the pa-
tients with STGD whom we studied but also with a
surprisingly high allele frequency, 1/88, in control in-
dividuals. Other authors have also remarked on this
phenomenon, and they have calculated that the pre-
dicted homozygote frequency for this allele alone is
greater than the estimated 1/10,000 incidence of STGD
(Maugeri et al. 1999). Taking this, as well as the ob-
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served scarcity of 2588GrC homozygotes, into ac-
count, Maugeri et al. (1999) concluded that 2588GrC
is a mild mutation, causing disease only in combination
with a severe allele. We have tested an alternate hy-
pothesis—that this allele is not a disease-causing mu-
tation but rather a variant that is frequent in the general
population and, because of linkage disequilibrium with
another, as-yet undetected, mutation in ABCA4, has an
increased frequency in the population with STGD. We
sequenced both DNA strands of all 50 exons of the
ABCA4 gene in two patients with the 2588GrC alter-
ation, in whom the second disease allele was also
known. No additional alterations were detected in these
patients, a finding that provides no further clarification
for this remarkable observation.
Unlike previous studies, which have mostly applied
SSCP, the present study has used a combination of the
highly sensitive DGGE and dHPLC techniques to screen
the ABCA4 gene, using SSCP analysis only for exons
10 and 11. Applying these techniques, we have achieved
an overall detection rate of close to 58%, which is com-
parable to the results of previous large studies, which
have used primarily SSCP (e.g., see Lewis et al. 1999;
Maugeri et al. 1999). The undetected mutations have
been attributed to possible large DNA rearrangements
or alterations of the promoter or intronic sequences, all
undetectable by PCR-based methodologies; however,
one study addressing this issue by use of Southern blot
analysis revealed only a single additional DNA deletion
(Maugeri et al. 1999). To determine whether method-
ological limitations are the reason for the low detection
rate, the complete sequence analysis of the ABCA4 gene
in patients screening negative under the aforementioned
protocols will be required. It is also possible that some
cases without an ABCA4 mutation either represent phe-
nocopies or may be associated with different genes—for
example, as de novo mutations in autosomal dominant
loci. Several families have been described that show
dominant inheritance of a Stargardt-like phenotype (Ci-
bis et al. 1980; Lopez et al. 1990; Mansour 1992; Stone
et al. 1994; Zhang et al. 1994), and at least three loci
have been mapped, by genetic linkage analysis, to chro-
mosomal regions 4p (Kniazeva et al. 1999), 6q (Stone
et al. 1994), and 13q (Zhang et al. 1994). Unfortunately,
until these genes are cloned, it may be difficult to assess
their contribution, since a large number of cases of
STGD are single occurrences without a history of the
disease in the family.
In an attempt to correlate ABCA4 genotype to phe-
notype, it has been suggested that there is an association
between the location of ABCA4 gene mutations and
clinical severity, as defined by the age at onset of visual
impairment (Lewis et al. 1999). We have not observed
this trend for either missense or truncating mutations.
On the contrary, specific mutations are associated with
highly variable ages at onset; for example, compound
heterozygosity for the complex allele L541P-A1038V
and G1961E was found in patients with age at onset
of 9–25 years (table 5). Age at onset is an easily quan-
tifiable measurement, but it also appears to be highly
subjective and has been demonstrated to vary consid-
erably within families, independent of disease severity
(Lois et al. 1999).
Previous documentation of ABCA4 mutations in in-
dividuals with either AMD, STGD, CRD, or RP led to
the suggestion of a model in which ABCA4 mutations
can cause a spectrum of retinal disease, with the clinical
phenotype determined by the level of residual ABCA4-
protein activity (Rozet et al. 1997; Cremers et al. 1998;
Martinez-Mir et al. 1998; Maugeri et al. 1999). Sup-
porting this is the presence, in the cohort of patients
whom we studied, of patient STGD139, who is a carrier
of a homozygous frameshift mutation (5917delG) and
has, at a young age, a relatively severe phenotype, with
features suggestive of cone-rod dystrophy. Two addi-
tional patients, STGD108 and STGD121, each have a
truncating mutation (Y362X and R1300X) in combi-
nation with the splice-site mutation IVS405GrA. Al-
though both patients had an early onset of visual im-
pairment, their phenotypes appear to be somewhat
milder than that of patient STGD139. This is consistent
with previous clinical observations (Cremers et al.
1998), as well as with the findings in our exon-trapping
system that point to the retention, because of the normal
splicing at the mutant intervening sequence-40 donor
site in a percentage of transcripts, of residual activity
of the ABCA4 protein.
By the reasoning proposed under the residual activity
model, the mild end of the ABCA4-associated pheno-
typic spectrum would be AMD, resulting from either
homozygosity for a very mild mutation or heterozy-
gosity for a moderate or severe alteration. In this study,
comparing the frequency of the probable disease chro-
mosomes in the group with AMD versus that in the
control ,no significant difference between the number
of patients with AMD (18/200) and control individuals
(12/220) who harbor ABCA4 mutations (Fisher’s exact
test, two-tailed; ). Inclusion of alterations clas-Pp .19
sified as rare sequence variants similarly results in com-
parable numbers of ABCA4 alterations in the two
groups ( ). This stands in contrast to a recentPp .72
study, involving 15 research groups from the United
States and Europe, that specifically investigated the
frequency of two common ABCA4 variants, G1961E
and D2177N, in a large cohort (11,200 individuals
each) of patients with AMD and of controls (Allikmets
and The International ABCR Screening Consortium
2000). These two variants were found at significantly
different frequencies in the two study populations
(3.4% in the group with AMD vs. 0.95% in controls).
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The numbers of patients and controls included in our
study may be large enough to rule out a major contri-
bution of mutant ABCA4 alleles in predisposition to
AMD; however, they may not be of the size required to
allow more-modest effects to be discerned. This makes
it extremely difficult to determine the significance of
individual mutant ABCA4 alleles in the predisposition
to AMD, particularly those which are present in low
frequency in the general population. Given the current
technology, the analysis, in its entirety, of a large gene
such as ABCA4 still represents a challenging task. At
this juncture, it may therefore be more reasonable to
follow the approach that the consortium has chosen for
analysis of the more common variants for their contri-
butions to susceptibility to AMD. The findings in this
study point to additional variants (2588GrC, A1038V,
and R1898H) that are present in reasonable frequencies
in the German population and that may be worthwhile
candidates for further extended analyses in large-scale
international efforts.
Acknowledgments
We are grateful to M. Andrassi and C. Gerth (Regensburg)
for examining the patients with STGD, to D. Besch (Tu¨bingen),
D. Walker (Eye Care Centre Vancouver), and U. Kellner (Ber-
lin) for their referral of patients with STGD, and to the many
individuals and families who participated in this project. This
work was supported by Pro Retina Deutschland, Deutsche
Forschungsgemeinschaft We 1259/10-1 and Ap 57/3-1 grants,
and Fortu¨ne Grant 707-0-0.
Electronic-Database Information
Accession numbers and URLs for data in this article are as
follows:
Online Mendelian Inheritance in Man (OMIM), http://www
.ncbi.nlm.nih.gov/Omim/ (for STGD1 [MIM 248200] and
ABCA4 [MIM 601691])
Statistisches Bundesamt Deutschland, http://www.statistik
-bund.de
References
Allikmets R, The International ABCR Screening Consortium
(2000) Further evidence for an association of ABCR alleles
with age-related macular degeneration. Am J Hum Genet
67:487–491
Allikmets R, Shroyer NF, Singh N, Seddon JM, Lewis RA,
Bernstein PS, Peiffer A, Zabriskie NA, Li Y, Hutchinson A,
Dean M, Lupski JR, Leppert M (1997a) Mutation of the
Stargardt disease gene (ABCR) in age-related macular de-
generation. Science 277:1805–1807
Allikmets R, Singh N, Sun H, Shroyer NF, Hutchinson A,
Chidambaram A, Gerrard B, Baird L, Stauffer D, Peiffer A,
Rattner A, Smallwood P, Li Y, Anderson KL, Lewis RA,
Nathans J, Leppert M, Dean M, Lupski JR (1997b) A pho-
toreceptor cell-specific ATP-binding transporter gene
(ABCR) is mutated in recessive Stargardt macular dystrophy.
Nat Genet 15:236–246
Bird AC, Bressler NM, Bressler SB, Chisholm IH, Coscas G,
Davis MD, de Jong PT, Klaver CC, Klein BE, Klein R,Mitch-
ell P, Sarks JP, Sarks SH, Soubrane G, Taylor HP, Vingerling
JR (1995) An international classification and grading system
for age-related maculopathy and age-related macular de-
generation. The International ARM Epidemiology Study
Group. Surv Ophthalmol 39:367–374
Bressler NM, Bressler SB, Fine SL (1988) Age-related macular
degeneration. Surv Ophthalmol 32:375–413
Cibis GW, Morey M, Harris DJ (1980) Dominantly inherited
macular dystrophy with flecks (Stargardt). ArchOphthalmol
98:1785–1789
Cotton RGH, Scriver CR (1998) Proof of “disease causing”
mutation. Hum Mutat 12:1–3
Cremers FP, van de Pol DJ, van Driel M, den Hollander AI,
van Haren FJ, Knoers NV, Tijmes N, Bergen AA, Rohr-
schneider K, Blankenagel A, Pinckers AJ, Deutman AF,
Hoyng CB (1998) Autosomal recessive retinitis pigmentosa
and cone-rod dystrophy caused by splice site mutations in
the Stargardt’s disease gene ABCR. Hum Mol Genet 7:
355–362
Dean M, Allikmets R, Shroyer NF, Lupski JR, Lewis RA, Lep-
pert M, Bernstein PS, Seddon JM (1998) ABCR gene and
age-related macular degeneration. Science 279:1107a
Dryja TP, Briggs CE, Berson EL (1998) ABCR gene and age-
related macular degeneration. Science 279:1107a
Fishman GA, Stone EM, Grover S, Derlacki DJ, Haines HL,
Hockey RR (1999) Variation of clinical expression in pa-
tients with Stargardt dystrophy and sequence variations in
the ABCR gene. Arch Ophthalmol 117:504–510
Fodde R, Losekoot M (1994) Mutation detection by denatur-
ing gradient gel electrophoresis (DGGE). Hum Mutat 3:
83–94
Klaver CCW, Assink JJM, Bergen AAB, van Duijn CM (1998)
ABCR gene and age-related macular degeneration. Science
279:1107a
Klein BE, Klein R, Linton KL (1992) Prevalence of age-related
maculopathy. The Beaver Dam Eye Study. Ophthalmology
99:933–943
Kniazeva M, Chiang MF, Morgan B, Anduze AL, Zack DJ,
Han M, Zhang K (1999) A new locus for autosomal dom-
inant Stargardt-like disease maps to chromosome 4. Am J
Hum Genet 64:1394–1399
Kra¨mer F, White K, Pauleikhoff D, Gehrig A, Passmore L,
Rivera A, Rudolph G, Kellner U, Andrassi M, Lorenz B,
Rohrschneider K, Blankenagel A, Jurklies B, Schilling H,
Schutt F, Holz FG, Weber BHF (2000) Mutations in the
VMD2 gene are associated with juvenile-onset vitelliform
macular dystrophy (Best disease) and adult vitelliform mac-
ular dystrophy but not age-related macular degeneration.
Eur J Hum Genet. 8:286–292
Lewis RA, Shroyer NF, Singh N, Allikmets R, Hutchinson A,
Li Y, Lupski JR, Leppert M, Dean M (1999) Genotype/
phenotype analysis of a photoreceptor-specific ATP-binding
cassette transporter gene, ABCR in Stargardt disease. Am J
Hum Genet 64:422–434
Liu W, Smith DI, Rechtizigel KJ, Thibodeau SN, James CD
Rivera et al.: Sequence Variations in the ABCA4 Gene 813
(1998) Denaturing high performance liquid chromatogra-
phy (DHPLC) used in the detection of germline and somatic
mutations. Nucleic Acids Res 26:1396–1400
Lois N, Holder GE, Fitzke FW, Plant C, Bird AC (1999) In-
trafamilial variation of phenotype in Stargardt macular dys-
trophy—fundus flavimaculatus. Invest Ophthalmol Vis Sci
40:2668–2675
Lopez PF, Maumenee IH, de la Cruz Z, Green WR (1990)
Autosomal-dominant fundus flavimaculatus: clinicopatho-
logic correlation. Ophthalmology 97:798–809
Mansour AM (1992) Long-term follow-up of dominant mac-
ular dystrophy with flecks (Stargardt). Ophthalmologica
205:138–143
Martinez-Mir A, Paloma E, Allikmets R, Ayuso C, del Rio T,
Dean M, Vilageliu L, Gonzalez-Duarte R, Balcells S (1998)
Retinitis pigmentosa caused by a homozygous mutation in
the Stargardt disease gene ABCR. Nat Genet 18:11–12
Maugeri A, van Driel MA, van de Pol DJ, Klevering BJ, van
Haren FJ, Tijmes N, Bergen AA, Rohrschneider K, Blan-
kenagel A, Pinckers AJ, Dahl N, Brunner HG, Deutman AF,
Hoyng CB, Cremers FP (1999) The 2588GrC mutation in
the ABCR gene is a mild frequent founder mutation in the
Western European population and allows the classification
of ABCR mutations in patients with Stargardt disease. Am
J Hum Genet 64:1024–1035
Molday LL, Rabin AR, Molday RS (2000) ABCR expression
in foveal cone photoreceptors and its role in Stargardt mac-
ular dystrophy. Nat Genet 25: 257–258
Nasonkin I, Illing M, Koehler MR, Schmid M, Molday RS,
Weber BHF (1998) Mapping of the rod photoreceptor
ABC transporter (ABCR) to 1p21-p22.1 and identification
of novel mutations in Stargardt’s disease. Hum Genet 102:
21–26
Orita M, Iwahana H, Kanazawa H, Hayashi K, Sekiya T
(1989) Detection of polymorphisms of human DNA by gel
electrophoresis as single-strand conformation polymor-
phisms. Proc Natl Acad Sci USA 86:2766–2770
Papaioannou M, Ocaka L, Bessant D, Lois N, Bird A, Payne
A, Bhattacharya S (2000) An analysis of ABCR mutations
in British patients with recessive retinal dystrophies. Invest
Ophthalmol Vis Sci 41:16–19
Papermaster DS, Schneider BG, Zorn MA, Kraehenbuhl JP
(1978) Immunocytochemical localization of a large intrinsic
membrane protein to the incisures and margins of frog rod
outer segment disks. J Cell Biol 78:415–425
Rozet JM, Gerber S, Souied E, Perrault I, Chatelin S, Ghazi I,
Leowski C, Dufier JL, Munnich A, Kaplan J (1998) Spec-
trum of ABCR gene mutations in autosomal recessive mac-
ular dystrophies. Eur J Hum Genet 6:291–295
Simonelli F, Testa F, de Crecchio G, Rinaldi E, Hutchinson A,
Atkinson A, Dean M, D’Urso M, Allikmets R (2000) New
ABCR mutations and clinical phenotype in Italian pa-
tients with Stargardt disease. Invest Ophthalmol Vis Sci 41:
892–897
Souied EH, Ducroq D, Rozet JM, Gerber S, Perrault I, Mun-
nich A, Coscas G, Soubrane G, Kaplan J (2000) ABCR gene
analysis in familial exudative age-related macular degener-
ation. Invest Ophthalmol Vis Sci 41:244–247
Stargardt K (1909) U¨ber familia¨re, progressive Degeneration
in der Maculagegend des Auges. Graefes Arch Ophthalmol
71:534–550
Stone EM, Nichols BE, Kimura AE, Weingeist TA, Drack A,
Sheffield VC (1994) Clinical features of a Stargardt-like
dominant progressive macular dystrophy with genetic link-
age to chromosome 6q. Arch Ophthalmol 112:765–772
Stone EM, Webster AR, Vandenburgh K, Streb LM, Hockey
RR, Lotery AJ, Sheffield VC (1998) Allelic variation in
ABCR associated with Stargardt disease but not age-related
macular degeneration. Nat Genet 20:328–329
Sun H, Molday RS, Nathans J (1999) Retinal stimulates ATP
hydrolysis by purified and reconstituted ABCR, the photo-
receptor-specific ATP-binding cassette transporter respon-
sible for Stargardt disease. J Biol Chem 274:8269–8281
Sun H, Nathans J (1997) Stargardt’s ABCR is localized to the
disc membrane of retinal rod outer segments. Nat Genet 17:
15–16
Weng J, Mata NL, Azarian SM, Tzekov RT, Birch DG, Travis
GH (1999) Insights into the function of Rim protein in pho-
toreceptors and etiology of Stargardt’s disease from the phe-
notype in abcr knockout mice. Cell 98:13–23
Zhang K, Bither PP, Park R, Donoso LA, Seid-
man JG, Seidman CE (1994) A dominant Stargardt’s mac-
ular dystrophy locus maps to chromosome 13q34. Arch
Ophthalmol 112:759–764
